Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

One item to point out is that Tvardi Therapeutics (TVRD) brought its pipeline forth to public trading because of a merger it enacted with Cara Therapeutics and thus was able to list on the NASDAQ. At ...

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pulmonary fibrosis, has ...

Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary ...

SHANGHAI, Feb. 11, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

It might start with a shortness of breath that’s easily dismissed as getting older or needing more exercise. But for the nearly 3 million patients with idiopathic pulmonary fibrosis (IPF), this subtle ...